Annals of Oncology Advance Access originally published online on April 10, 2007
Annals of Oncology 2007 18(11):1765-1773; doi:10.1093/annonc/mdm086
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2007 European Society for Medical Oncology
reviews |
The role of Src in prostate cancer
Department of Medicine, Institut Gustave-Roussy, 39 rue Camille Desmoulins, 94800 Villejuif, France
* Correspondence to: Dr Karim Fizazi, Department of Medicine, Institut Gustave-Roussy, 39 rue Camille Desmoulins, 94800 Villejuif, France. Tel: +33-1-42-11-62-64; Fax: +33-1-42-11-52-30; E-mail: fizazi{at}igr.fr
The Src family kinases (SFKs) are the largest family of nonreceptor protein tyrosine kinases and are responsible for signal transduction during many cellular activities, including differentiation, adhesion, and migration. Aberrant Src/SFK activity has been widely implicated in cancer development. Several lines of evidence indicate a role for SFKs in the development of prostate cancer, e.g. SFK overexpression in prostate cancer cell lines and tissues and reduced cancer cell proliferation, invasion, and migration following Src inhibition. In particular, Src may be involved in androgen-independent growth during advanced stages of disease. Src signaling is also a key pathway during normal and dysregulated bone functioning, and bone metastases are responsible for substantial morbidity in advanced prostate cancer. Src/SFK inhibition therefore represents a potentially useful therapeutic strategy for patients with various stages of prostate cancer. To date, four Src inhibitors have reached clinical trials. Of these, the broadest range of in vitro prostate cancer data are available for dasatinib, which inhibits several SFKs as well as other tyrosine kinases. Src inhibitors may be specifically evaluated in prostate cancer clinical trials in the near future.
Key words: dasatinib, prostate cancer, Src, Src family kinase, Src inhibitors
Received for publication December 22, 2006. Revision received February 7, 2007. Accepted for publication February 8, 2007.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  E. Y. Yu, G. Wilding, E. Posadas, M. Gross, S. Culine, C. Massard, M. J. Morris, G. Hudes, F. Calabro, S. Cheng, et al. Phase II Study of Dasatinib in Patients with Metastatic Castration-Resistant Prostate Cancer Clin. Cancer Res., December 1, 2009; 15(23): 7421 - 7428. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. J. Armstrong and P. G. Febbo Using Surrogate Biomarkers to Predict Clinical Benefit in Men with Castration-Resistant Prostate Cancer: An Update and Review of the Literature Oncologist, August 1, 2009; 14(8): 816 - 827. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. E. Schweppe, A. A. Kerege, J. D. French, V. Sharma, R. L. Grzywa, and B. R. Haugen Inhibition of Src with AZD0530 Reveals the Src-Focal Adhesion Kinase Complex as a Novel Therapeutic Target in Papillary and Anaplastic Thyroid Cancer J. Clin. Endocrinol. Metab., June 1, 2009; 94(6): 2199 - 2203. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Fizazi, P. Beuzeboc, J. Lumbroso, V. Haddad, C. Massard, M. Gross-Goupil, M. Di Palma, B. Escudier, C. Theodore, Y. Loriot, et al. Phase II Trial of Consolidation Docetaxel and Samarium-153 in Patients With Bone Metastases From Castration-Resistant Prostate Cancer J. Clin. Oncol., May 20, 2009; 27(15): 2429 - 2435. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. M. Attar, C. H. Takimoto, and M. M. Gottardis Castration-Resistant Prostate Cancer: Locking Up the Molecular Escape Routes Clin. Cancer Res., May 15, 2009; 15(10): 3251 - 3255. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Hayes and S. E. Moss Annexin 2 Has a Dual Role as Regulator and Effector of v-Src in Cell Transformation J. Biol. Chem., April 10, 2009; 284(15): 10202 - 10210. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Fizazi, A. Lipton, X. Mariette, J.-J. Body, Y. Rahim, J. R. Gralow, G. Gao, L. Wu, W. Sohn, and S. Jun Randomized Phase II Trial of Denosumab in Patients With Bone Metastases From Prostate Cancer, Breast Cancer, or Other Neoplasms After Intravenous Bisphosphonates J. Clin. Oncol., April 1, 2009; 27(10): 1564 - 1571. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W.-Y. Kim, D. J. Chang, B. Hennessy, H. J. Kang, J. Yoo, S.-H. Han, Y.-S. Kim, H.-J. Park, S.-Y. Geo, G. Mills, et al. A Novel Derivative of the Natural Agent Deguelin for Cancer Chemoprevention and Therapy Cancer Prevention Research, December 1, 2008; 1(7): 577 - 587. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. C. Siva, M. A. Wild, R. E. Kirkland, M. J. Nolan, B. Lin, T. Maruyama, F. Yantiri-Wernimont, S. Frederickson, K. S. Bowdish, and H. Xin Targeting CUB Domain-Containing Protein 1 with a Monoclonal Antibody Inhibits Metastasis in a Prostate Cancer Model Cancer Res., May 15, 2008; 68(10): 3759 - 3766. [Abstract] [Full Text] [PDF]
|
|